Teva and Mylan Are Adapting to the Challenging Generic Industry Dynamics
We took a fresh deep dive into our analysis for Teva and Mylan and continue to view the companies with no moats. The two controversial healthcare names have been battered by generic drug pricing pressure, confluence of legal matters, and concern over high debt loads. The market backdrop has made it critical to focus on rapidly replenishing their generic and specialty pipelines, aggressively right size their infrastructures, and flex their scale to fend off international competitors with signific...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.